Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t imply causality however lack of improvement by tocilizumab requires further clinical trial alterations.
All Keywords
【저자키워드】 Diseases, Outcomes research, 【초록키워드】 clinical trial, Mortality, Tocilizumab, IL-6, Cytokine release syndrome, COVID-19 patient, tocilizumab administration, lack, elevated, correlated, reflect, alterations, COVID-19 pneumonia patient, IL-6 level, 【제목키워드】 Mortality, Tocilizumab, COVID19 patient,
【저자키워드】 Diseases, Outcomes research, 【초록키워드】 clinical trial, Mortality, Tocilizumab, IL-6, Cytokine release syndrome, COVID-19 patient, tocilizumab administration, lack, elevated, correlated, reflect, alterations, COVID-19 pneumonia patient, IL-6 level, 【제목키워드】 Mortality, Tocilizumab, COVID19 patient,